Effectiveness and safety of short course liposomal amphotericin B (AmBisome) as first line treatment for visceral leishmaniasis in Bangladesh.

Effectiveness and safety of short course liposomal amphotericin B (AmBisome) as first line treatment for visceral leishmaniasis in Bangladesh.

BACKGROUND:Bangladesh is one of the endemic countries for Visceral Leishmaniasis (VL). Médecins Sans Frontières (MSF) ran a VL treatment clinic in the most endemic district (Fulbaria) between 2010 and 2013 using a semi-ambulatory regimen for primary VL of 15 mg/kg Liposomal Amphotericin-B (AmBisome)...

Full description

Bibliographic Details
Main Authors:	Emiliano Lucero, Simon M Collin, Sujit Gomes, Fatima Akter, Asaduzzam Asad, Asish Kumar Das, Koert Ritmeijer
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2015-04-01
Series:	PLoS Neglected Tropical Diseases
Online Access:	http://europepmc.org/articles/PMC4383421?pdf=render

Similar Items

A randomized trial of AmBisome monotherapy and AmBisome and miltefosine combination to treat visceral leishmaniasis in HIV co-infected patients in Ethiopia.
by: Ermias Diro, et al.
Published: (2019-01-01)

The initial effectiveness of liposomal amphotericin B (AmBisome) and miltefosine combination for treatment of visceral leishmaniasis in HIV co-infected patients in Ethiopia: A retrospective cohort study.
by: Charles Abongomera, et al.
Published: (2018-05-01)

Immediate hypersensitivity reaction following liposomal amphotericin-B (AmBisome) infusion.
by: Nath, P, et al.
Published: (2014)

Visceral leishmaniasis and HIV co-infection in Bihar, India: long-term effectiveness and treatment outcomes with liposomal amphotericin B (AmBisome).
by: Sakib Burza, et al.
Published: (2014-08-01)

Comparative efficacy, toxicity and biodistribution of the liposomal amphotericin B formulations Fungisome® and AmBisome® in murine cutaneous leishmaniasis
by: Gert-Jan Wijnant, et al.
Published: (2018-08-01)

Hypokalaemia-induced rhabdomyolysis after treatment of post-Kala-azar dermal Leishmaniasis (PKDL) with high-dose AmBisome in Bangladesh-a case report.
by: Ulrika Marking, et al.
Published: (2014-06-01)

Cytotoxicity of Amphotericin B and AmBisome: In Silico and In Vivo Evaluation Employing the Chick Embryo Model
by: Ahmad Khosravi, et al.
Published: (2022-06-01)

Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh.
by: Ridwanur Rahman, et al.
Published: (2017-05-01)

Efficacy and Safety of AmBisome in Combination with Sodium Stibogluconate or Miltefosine and Miltefosine Monotherapy for African Visceral Leishmaniasis: Phase II Randomized Trial.
by: Monique Wasunna, et al.
Published: (2016-09-01)

Parasitic loads in tissues of mice infected with Trypanosoma cruzi and treated with AmBisome.
by: Sabrina Cencig, et al.
Published: (2011-06-01)

AmBisome<sup>®</sup> Formulations for Pediatrics: Stability, Cytotoxicity, and Cost-Effectiveness Studies
by: Guendalina Zuccari, et al.
Published: (2024-03-01)

Combination therapy with liposomal amphotericin b (ambisome), n-methylglucamine antimoniate (glucantime), and pentamidine isethionate in a refractory visceral leishmaniasis case
by: Maria Antonia Ferreira Gomes, et al.

High loading dose AmBisome® is efficacious and well tolerated in the management of invasive fungal infection in hematology patients
by: Lorna A. McLintock, et al.
Published: (2007-04-01)

Correction: Risk Factors for Visceral Leishmaniasis Relapse in Immunocompetent Patients following Treatment with 20 mg/kg Liposomal Amphotericin B (Ambisome) in Bihar, India
Published: (2014-04-01)

Correction: Five-Year Field Results and Long-Term Effectiveness of 20 mg/kg Liposomal Amphotericin B (Ambisome) for Visceral Leishmaniasis in Bihar, India
Published: (2014-04-01)

Correction: Risk Factors for Visceral Leishmaniasis Relapse in Immunocompetent Patients following Treatment with 20 mg/kg Liposomal Amphotericin B (Ambisome) in Bihar, India.
Published: (2014-04-01)

Liposomal amphotericin B in drug-resistant visceral leishmaniasis.
by: Davidson, R, et al.
Published: (1991)

Different liposomal amphotericin B formulations for visceral leishmaniasis
by: Thomas P C Dorlo, et al.
Published: (2014-08-01)

Single-dose liposomal amphotericin B for visceral leishmaniasis
by: Nilima A Kshirsagar
Published: (2014-04-01)

Antimony to Cure Visceral Leishmaniasis Unresponsive to Liposomal Amphotericin B.
by: Gloria Morizot, et al.
Published: (2016-01-01)

Different liposomal amphotericin B formulations for visceral leishmaniasis–Author's reply
by: Nilima Kshirsagar
Published: (2014-08-01)

Foamy histiocytes in a patient with visceral leishmaniasis after treatment with liposomal amphotericin B
by: Betül Tavil, et al.
Published: (2008-02-01)

Combined immunotherapeutic effect of Leishmania-derived recombinant aldolase and Ambisome against experimental visceral leishmaniasis
by: Keerti, et al.
Published: (2023-02-01)

Liposomal amphotericin B and leishmaniasis: Dose and response
by: Shyam Sundar, et al.
Published: (2010-01-01)

Visceral Leishmaniasis in Children in Southern Turkey: Evaluation of Clinical and Laboratory Findings and Liposomal Amphotericin B Treatment
by: Barbaros Şahin Karagün, et al.
Published: (2019-06-01)

Treatment of Complex Cutaneous Leishmaniasis with Liposomal Amphotericin B
by: Maria Ubals, et al.
Published: (2021-09-01)

Visceral Leishmaniasis and HIV coinfection in East Africa.
by: Ermias Diro, et al.
Published: (2014-06-01)

Introducing Single Dose Liposomal Amphotericin B for the Treatment of Visceral Leishmaniasis in Rural Bangladesh: Feasibility and Acceptance to Patients and Health Staff
by: Eva-Maria Maintz, et al.
Published: (2014-01-01)

Visceral leishmaniasis and Coombs' positive hemolytic anemia: a rare association in an infant treated with liposomal amphotericin B
by: Embiya Dilber, et al.
Published: (2002-10-01)

Anticipating visceral leishmaniasis epidemics due to the conflict in Northern Ethiopia.
by: Carl Boodman, et al.
Published: (2023-03-01)

Anticipating visceral leishmaniasis epidemics due to the conflict in Northern Ethiopia
by: Carl Boodman, et al.
Published: (2023-03-01)

Visceral leishmaniasis as an AIDS defining condition: towards consistency across WHO guidelines.
by: Johan van Griensven, et al.
Published: (2014-07-01)

Disseminated tegumentary leishmaniasis refractory to liposomal amphotericin B treatment
by: Ana Flávia Borges, et al.
Published: (2021-03-01)

Reversible Ototoxicity: A Rare Adverse Reaction of Liposomal Amphotericin-B Used for the Treatment of Antimony-Resistant Visceral Leishmaniasis in an Elderly Male
by: PC Das, et al.
Published: (2014-07-01)

Efficacy and safety of amphotericin B emulsion versus liposomal formulation in Indian patients with visceral leishmaniasis: a randomized, open-label study.
by: Shyam Sundar, et al.
Published: (2014-09-01)

Liposomal amphotericin B versus pentavalent antimony salts for visceral Leishmania in children
by: Hurşit Apa, et al.
Published: (2013-08-01)

Peroral amphotericin B polymer nanoparticles lead to comparable or superior in vivo antifungal activity to that of intravenous Ambisome® or Fungizone™.
by: Jagdishbhai L Italia, et al.
Published: (2011-01-01)

Liposomal amphotericin B in travelers with cutaneous and muco-cutaneous leishmaniasis: Not a panacea.
by: Romain Guery, et al.
Published: (2017-11-01)

Development of a topical liposomal formulation of Amphotericin B for the treatment of cutaneous leishmaniasis
by: Mahmoud Reza Jaafari, et al.
Published: (2019-12-01)

"SUCCESSFUL TREATMENT WITH AMPHOTERICIN B OF PATIENTS WITH VISCERAL LEISHMANIASIS RESISTANT TO MEGLUMINE ANTIMONATE"
by: P. Tabatabaie, et al.
Published: (2004-05-01)